It is an open question whether in multiple myeloma (MM) bone marrow stromal cells contain genomic alterations, which may contribute to the pathogenesis of the disease. We conducted an array-based comparative genomic hybridization (array-CGH) analysis to compare the extent of unbalanced genomic alterations in mesenchymal stem cells from 21 myeloma patients (MM-MSCs) and 12 normal donors (ND-MSCs) after in vitro culture expansion. Whereas ND-MSCs were devoid of genomic imbalances, several non-recurrent chromosomal gains and losses (41 Mb size) were detected in MM-MSCs. Using realtime reverse transcription PCR, we found correlative deregulated expression for five genes encoded in regions for which genomic imbalances were detected using array-CGH. In addition, only MM-MSCs showed a specific pattern of 'hot-spot' regions with discrete (o1 Mb) genomic alterations, some of which were confirmed using fluorescence in situ hybridization (FISH). Within MM-MSC samples, unsupervised cluster analysis did not correlate with particular clinicobiological features of MM patients. We also explored whether cytogenetic abnormalities present in myelomatous plasma cells (PCs) were shared by matching MSCs from the same patients using FISH. All MMMSCs were cytogenetically normal for the tested genomic alterations. Therefore we cannot support a common progenitor for myeloma PCs and MSCs.
Introduction
Multiple myeloma (MM) is a B-cell neoplasia characterized by accumulation of clonal plasma cells (PC) in the bone marrow, the presence of monoclonal immunoglobulin in blood and/or urine, and the existence of bone lesions. The genetic basis of the disease includes recurrent and complex genetic abnormalities in myelomatous cells, which besides contributing to the pathogenesis of MM also influences the heterogeneous clinical course of the disease. [1] [2] [3] In addition, the involvement of the bone marrow (BM) microenvironment in the pathophysiology of the disease is nowadays well-accepted. [4] [5] [6] [7] This contribution is mediated either directly by interactions of myeloma cells with BM stromal cells and extracellular matrix proteins or indirectly by secretion of soluble cytokine and growth factors by myeloma cells and/or stromal cells. These interactions and growth factor circuits ultimately lead to the activation of pleiotrophic signalling cascades, which promote proliferation, cell survival, antiapoptotic signalling, drug resistance and migration of MM cells. 4, 5, 7 Furthermore, crosstalk of myeloma cells with other cells in the BM milieu, such as osteoblasts and osteoclasts, results in inhibition of the former and activation of the latter, which produces an unbalanced bone remodelling responsible for the development of bone lesions in MM patients. 6, 8, 9 Bone marrow mesenchymal stem cells (MSCs) are an essential cell type in the formation and function of the BM microenvironment, being the progenitor cells of osteoblasts and the haemopoietic-supporting stroma components of the marrow. 10, 11 In fact, differences between MSCs derived from MM patients (MM-MSCs) and those from healthy donors (ND-MSCs) have been reported. [12] [13] [14] [15] [16] When compared with their normal counterparts, MM-MSCs differ in spontaneous and myeloma cell-induced production of cytokines, exhibit a decreased proliferative capacity and present reduced efficiency to inhibit T-cell proliferation, and the osteoblasts derived from MM-MSCs show a diminished matrix mineralization potential when compared with their normal counterparts. [12] [13] [14] [15] [16] Moreover, Corre et al. 13 have observed a distinctive gene expression profile for MM-MSCs and ND-MSCs upon using microarray analysis, with differential expression of genes coding for growth and angiogenic factors, as well as for factors related to bone differentiation. 13 All these differences were detected after MSCs isolation and expansion in culture. Although it has been suggested that these differences between normal and myelomatous MSCs could be attributed to the presence of genomic alterations in MM-MSCs, [12] [13] [14] this is still an issue to be clarified. On the other hand, the clinical observation that bone lesions from MM patients do not heal even after response to therapy 9, 17 also seems to support the idea of a permanent defect in the capacity of MM-MSCs to generate fully functional bonegenerating osteoblasts. This last issue could also be explained by genomic alterations present in MM-MSCs, which would remain in the absence of myeloma cells.
An additional controversial issue in the field of MSCs is the idea of a common haematopoietic and mesenchymal progenitor, with occasional reports favouring this possibility. [18] [19] [20] Theoretically, if MSCs from myeloma patients would encompass cytogenetic markers present in myelomatous PCs, the genomic events leading to those genomic aberrations should have occurred earlier to a mesenchymal or haematopoietic commitment, thus supporting the idea of a common precursor for both types of cells.
To gain insight into these questions, we carried out a genomewide scan on MSCs derived from MM patients and healthy donors using array-based comparative genomic hybridization (array-CGH). This technique has already been successfully used to explore the presence of gains and losses of genetic material in several types of cancer [21] [22] [23] [24] [25] and also to discriminate, within the genomic alteration, the contribution of the stromal vs epithelial compartments. 26 Besides, we have also explored the presence of genomic alterations of myelomatous PCs in the matching MSCs from the same patients using fluorescence in situ hybridization (FISH).
Materials and methods

Participants
A total of 26 patients with newly diagnosed MM were included in this study (median age was 68 years, ranging from 28 to 89 years). Characteristics of the patients are listed in Table 1 . A total of 12 healthy controls of BM samples were obtained from participants undergoing orthopaedic surgery, with a similar age range to MM patients (median age 58 years, range 26-88 years). Every sample was obtained after receiving informed written consent of patients and donor volunteers and following approval from the Ethical Committee of our Institution.
MSC harvest, culture conditions and characterization
Mononuclear cells from BM samples were obtained after density gradient centrifugation using Ficoll-Paque Premium 1.073 (GE Healthcare, Uppsala, Sweden) and cultured in low-glucose Dubecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 1% L-glutamine. After 3 or 4 days in culture, non-adherent cells were removed, whereas MSCs were selected by their adherence to the plasticware (this was considered as passage 0, P0). 10 For five selected donors, the non-adherent fraction was not discarded, but harvested to obtain a normal control DNA for array-CGH hybridization. The culture medium was replaced twice weekly until MSC cultures were approximately 90% confluent or had remained a maximum of 21 days in culture; at this point, cells were trypsinized (0.05% trypsin-EDTA) and expanded in a 1:3 ratio (P1). The MSCs were collected near confluency at P3 for subsequent genomic DNA isolation or FISH studies. No apparent haematological cell contamination was observed under the microscope at the time of MSC harvest. The cultures were maintained at 37 1C and 5% CO 2 . All the cell culture media and reagents were purchased from Invitrogen (Paisley, UK).
Selected MSCs from both MM patients (n ¼ 4) and healthy donors (n ¼ 4) at P3 were also tested to meet the minimal criteria as defined by the International Society for Cellular Therapy for multipotent mesenchymal stromal cells. 27 These criteria included specific cell surface antigen expression and trilineage mesenchymal differentiation potential. Combinations of monoclonal antibodies anti-CD34-APC (allophycocyanine), -CD19-APC, -CD45-PerCPCy5.5, -HLA-DR-PerCPCyC5.5, -CD14-FITC (fluorescein isothiocyanate) (Becton-Dickinson Biosciences, San José, CA, USA), -CD90-FITC (allophycocyanine), -CD73-PE, -CD166-PE, -CD106-PE (BD Biosciences Pharmingen, San José, CA, USA) and anti-CD105-FITC (ImmunoStep, Salamanca, Spain) were used to label 5 Â 10 5 cells at dilutions recommended by the manufacturers. The appropriate isotopic control In addition, osteogenic, adipogenic and chondrogenic differentiation was also confirmed in four MM-MSC and four ND-MSC samples at P3 using standard in vitro tissue culturedifferentiating conditions. In brief, for osteoblastic and adipocytic differentiations, 80% confluent MSCs were grown for 2 or 3 weeks in a specific differentiation medium changing the medium on every fourth day (a minimal essential medium supplemented with 10% fetal bovine serum, 10 mM b-glycerol phosphate (Sigma-Aldrich, St Louis, MO, USA), 50 mg/ml ascorbic acid and 10nM dexamethasone for osteoblasts, or NH AdipoDiff medium (Macs Media, Miltenyi Biotec, Bergisch Gladbach, Germany) for adipocytes). To induce chondrocytic differentiation, a MSC pellet was maintained in a conical polypropylene tube with NH ChondroDiff medium (Mitenyi Biotec) for 24 days changing the medium on every third day. Evaluation of osteocytic, adipocytic or chondrocytic differentiations of MSCs was achieved using alkaline phosphatase, Oil-Red-O, and Masson's trichrome stainings, respectively.
Sorting of MSCs
Isolation of MSCs directly from BM aspirates was carried out in five MM patients (No. 22-26 in Table 1 ), using a FACSAria flow cytometer equipped with the FACSDiva software (Becton Dickinson Biosciences) as described earlier. 28 In brief, cells were stained with a single four-color combination of monoclonal antibodies: anti-CD45-FITC (Miltenyi Biotec)/anti-CD73-PE (BD Biosciences Pharmingen, San José, CA, USA)/ antiCD34-PeCy5 (Immunotech Coulter Company, Marseille, France)/anti-CD271-APC (Miltenyi Biotec). Isolation of MSCs was achieved by sorting of BM cells with the CD45
Owing to the low proportion of MSCs in the sample, acquisition of MSCs was carried out through a 'live gate' drawn on the CD73 þ /CD271 þ region of the total nucleated cells present in the sample. The purity of the isolated MSC populations was 99%.
Array-based comparative genomic hybridization of MSCs at passage 3
The DNA from MSCs was isolated after trypsinization of cells reaching 90% confluency at P3, using the Qiamp DNA Mini kit (Qiagen GmbH, Hilden, Germany). Normal DNA was prepared from human placenta of healthy donors using standard methods. Genomic-wide survey of DNA copy number changes from 21 cases of MM-MSCs and 12 ND-MSCs was carried out using array-CGH. Slides containing 3528 bacterial artificial chromosomes (BACs) spanning the full genome at E1-Mb density were produced at our institution as distributed by the Welcome Trust Sanger Institute (Cambridge, United Kingdom; clone content is available in the 'Cytoview' windows of the Sanger Institute mapping database site (http://www.ensembl.org/). In brief, reference genomic DNA (DNA of placenta) and non-amplified genomic test DNA (DNA from MSCs) were separately digested and labelled with Cy3-dCTP or Cy5-dCTP. Paired hybridization samples were then cohybridized to the arrays in a HS 4800 ProTecan (Tecan, Männedorf, Switzerland) hybridizer for 48 h at 42 1C according to the manufacturer's recommended protocol. For each microarray, data from two-color hybridizations were normalized using print-tip loess method with the Diagnosis and Normalization Module Arrays Data Tool of the GEPAS software. 29 Many threshold values to identify gains or losses in array-CGH analyses have been reported in the literature depending on the type of study. 30 We carried out array-CGH analyses of five 'normal to normal hybridizations' (genomic DNA from the mononuclear fraction of five selected donors and genomic DNA from placenta) and identified the median ± 3s.d. as the cutoff level to use in our study. Owing to the resolution of our array-CGH (75-100 kb length for each clone and E1 Mb spacing/intervals between the clones), at least two consecutive clones with log 2 ratios above or below our threshold value were needed to be considered as genomic gains or losses, respectively. Data sets were carefully reviewed for frequently affected chromosomal sites of physiological copy number polymorphisms (CNP: http://www.project.tcag.ca/variation and DECIPHER: http://www.decipher.sanger.ac.uk/perl/application/). 31 Detailed information of array-CGH production, hybridization and analysis is available in the Supplementary material 1.
Array-CGH on sorted MSCs
Genomic DNA from sorted MSCs was extracted using the Qiamp DNA Mini kit (Qiagen GmbH) and then subsequently amplified with the GenomiPhi DNA amplification kit (Amersham Biosciences, Piscataway, NJ, USA) following the manufacturer's instructions. In brief, genomic DNA was denatured at 95 1C and then amplified using the Phi29 DNA polymerase at 30 1C for 16 h. After heat inactivation of the enzyme, post-amplification cleanup was achieved by standard ethanol precipitation. The absence of human-specific sequences in non-specific amplification products was verified using PCR.
Array-CGH was carried out as described for MSCs at P3 with minor modifications. Essentially, amplified genomic DNAs from sorted MSCs were used as test DNAs. For each patient, genomic DNA from ammonium chloride-lysed peripheral blood, or otherwise, genomic DNA from CD138 À /CD271 À /CD73 À BMsorted cells were similarly isolated and amplified, and used as reference genomic DNAs. Both test and reference DNAs were amplified using the same amount of starting DNA.
Fluorescence in situ hybridization analyses
For each patient, MM-MSCs at P3 were grown on sterilized microscope slides and were used to examine the presence of specific genomic alterations found in the matching myeloma PCs using interphase FISH and standard protocols. 32 MSC pretreatment and probes used for detection of IGH translocation, specific IGH translocations, and 13q and 17p deletions can be consulted in Supplementary material 2. A total of 200 interphase nuclei were analysed for each probe in this study. ND-MSC interphases were used as controls.
To confirm selected genomic imbalances identified by array-CGH, FISH analysis was also carried out on MM-MSCs using DNA from correspondent BAC clones as specific probes (see Table 2 ). In brief, DNA was isolated and directly labelled with either digoxigenin-dUTP or biotin-dUTP using nick translation (Abbot Molecular Inc., Des Plaines, IL USA). After DNAse I-controlled digestion and further purification of the probe, FISH was carried out on correspondent MM-MSC slides using TRITC (tetramethyl rhodamine isothiocyanate)-or FITC-labelled secondary antibodies. A minimum of 100 interphase nuclei were scored.
Real-time PCR-based analyses
To check the most frequent single targets from array-CGH results, we carried out a relative quantification of DNA copy number of several genes using the Step One Plus Real-Time PCR System and the Fast SYBR-Green Master Mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA). Primer sequences for these genes and for the reference genes (albumin and RNAse P) are provided in Table 3 . Five ND-MSC DNA samples were tested as a calibrator. The arithmetic mean of replicated C t values for each gene was transformed to a relative quantity, using the equation ð1 þ EÞ ÀDDCt where E is the amplification efficiency, DC t ¼ C tGene À C t Control genes ðmeanÞ and DDC t ¼ DC tpatient À DC t calibrator ðmeanÞ . 33 Additional aspects of primer design and real-time PCR procedure for copy number variation are explained in Supplementary material 3. The expression level of certain genes located in array-CGHdetected gains (FBLN5, ZNF21, ITPK1) or losses (KCTD8, BMP10) of genomic DNA were also quantified using real-time RT-PCR. Total RNA was isolated from MSCs at passage 3 using the RNeasy Mini kit (Qiagen GmbH). Reverse transcription was carried out with 1.0 mg RNA in the presence of random hexamers and 100 U of SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For PCR reactions, we used the
Step One Plus Real-Time PCR System with TaqMan Fast Universal PCR Master Mix and TaqMan Gene Expression Assays (Applied Biosystems) according to the manufacturer's instructions. Experiments were carried out in duplicate for both the target and the endogenous gene (GAPDH). Relative quantification of the target gene expression was calculated using the comparative threshold cycle (Ct) method. The expression of a target gene was normalized to the expression of an endogenous control (GADPH), and presented relative to the expression in an experiment-specific calibrator (control patient with no genomic imbalances for the target gene). The value of the relative expression of the target gene was calculated using the equation 2 ÀDDCt where DC t ¼ C tTarget gene À C tGAPDH and DDC t ¼ DC t sample for target À DC t calibrator for target ðmeanÞ . Results in control patients were normalized by setting the corresponding value as 1. The assay IDs were: FBLN5, Hs00197064_m1; ZNF217, Hs00232417_m1; ITPK1, Hs356546_m1; KCTD8, Hs00957322_s1, and BMP10, Hs00205566_m1.
Data analyses
For unsupervised cluster analysis of array-CGH data, we converted the relative ratio value for each BAC clone to a score of 1 (gain/amplified), 0 (no change), or À1 (loss) based on the Statistical evaluation was carried out using the SPSS 15.0 statistical software. All P-values reported were two-sided and statistical significance was defined as P-values o0.05.
Results
Genomic changes in cultured ND-MSCs and MM-MSCs
When we looked for gene copy number variation on arrays from ND-MSCs, no evidence was found for genomic imbalances. By contrast, several chromosomal gains and losses were detected in MM-MSCs as defined by two consecutive-target BACs (regions 41 Mb) (see Tables 4 and 5 ). These DNA copy number changes were not recurrent within the patients. Only a chromosomal loss located at 4p14-4p13 was observed in 3 out of 21 MM-MSCs, and another loss at 3q13.13 was detected in MSCs from two patients. However, although these genomic alterations showed almost no recurrence within patients, in many cases the affected BACs were located within the same chromosomal region (encompassing a variable length of 6-15 Mb), so that in several patients the genomic alterations partially overlapped or were located nearby (see Figure 1) .
Presence of 'hot-spot' regions in cultured MM-MSC
When comparing along the genomic alterations of MSCs from both normal donors and MM patients, we observed that in the latter, there were specific regions of variable length in the genome, in which patients showed discrete alterations ('onetarget BAC alterations', o1 Mb in size) (Figure 2 ). We have named these regions as 'hot-spots' in MM-MSCs, and their specific location along the genome is depicted in Figure 3 . We found a predominance of hot-spots with discrete gains of genomic material over that of hot-spots with genomic losses. It should be noted that these abnormalities were present at a higher frequency than when two contiguous BACs were considered (see Supplementary Table 1) . Although some may argue against the specificity of these alterations, it is of interest that these regions of one-target BAC alterations were constantly absent in ND-MSCs (Figure 2 ).
Unsupervised analysis of genomic changes in cultured MSCs
When an unsupervised cluster analysis with array-CGH data from both ND-and MM-MSCs at P3 was carried out, the dendogram discerned two major clusters with common MSC origin (Figure 4) . One cluster contained all 12 ND-MSCs samples with only four MM-MSCs interspersed between them; these four samples from MM patients were found to have minimal genomic imbalances. The other cluster exclusively 
Array-CGH confirmatory studies using FISH and real-time PCR-based analyses
To confirm some of the results obtained using array-CGH, FISH studies were carried out on MSCs derived from MM patients at P3 and using DNA from selected BAC clones as specific probes (see Table 2 ). Four gains and four losses of genomic material were tested and confirmed using FISH ( Figure 5 ). It should be noted that only a percentage (ranging from 45 to 80%) of the scored MSCs were found to present a duplication or deletion of the correspondent DNA clone, whereas the rest of the cells remained diploid ( Figure 5 and Table 2 ).
We also attempted to confirm most recurrent gains or losses from the hot-spot regions using a real-time PCR assay for gene copy number variation and primers located at candidate genes within the gained or lost BACs (see Table 3 ). In this type of assay, a relative value of 1 should be expected for normal diploid copy number and, subsequently, a value of p0.5 would be associated with one allele deletion and a value X1.5 would be associated with one allele duplication. 33 Except for one case (BCMO1), real-time PCR was unable to detect DNA copy number variations (either gains or losses) observed using array-CGH (Figure 6a ). This discrepancy is probably related to the fact that the genomic alterations were present only in a fraction of MSCs, as shown above in FISH analyses.
In addition, we evaluated the RNA expression levels of five putatively affected genes using real-time RT-PCR, which were located within losses (KCTD8, BMP10; see Table 4 ) or gains (FBLN5, ZNF217, ITPK1; Table 5 ) of genomic material using array-CGH analysis. The expression of each target was calculated as the ratio between its expression on MM-MSC samples at P3 from patients carrying the genomic imbalance, and the mean expression of the same target gene on MSCs from patients with normal copy number for the affected BAC (control patient). As can be seen in Figure 6b , a downregulated expression of KCTD8 and BMP10 was observed in MSCs of patients with correspondent lost BACs; on the contrary, three out of four patients with a genomic gain at array-CGH level presented increased RNA levels for FBLN5, ZNF217 and ITPK1.
Array-CGH on sorted MM-MSCs
In five MM cases, array-CGH analysis was conducted after direct sorting of MSCs from BM aspirates. Although discrete gains or losses of genomic material (o1Mb) were observed in every sample, only one MM-MSC sample presented genomic gains 41 Mb in size (see Table 6 ).
MM-MSCs do not share cytogenetic alterations found in plasma cells
We also tested the presence of the cytogenetic aberrations of myelomatous cells in MSCs derived from the same patient using interphase FISH studies. From a total of 21 patients, PCs from 18 patients showed IGH translocations, or deletions of RB or P53, as assessed using FISH (see Table 1 ). In none of these 18 patients, MM-MSCs displayed the genetic abnormalities present in the correspondent myelomatous PCs (data not shown).
Discussion
Although the implication of the BM microenvironment in MM 4, 5, 7 (and that of the surrounding stroma in solid tumours [34] [35] [36] as key determinants in the malignant progression of cancer is nowadays well-accepted, it is not clear whether this role is in turn supported by genomic alterations of stromal cells, which can coevolve in the tumourigenesis process. 26 In fact, several independent groups have documented the existence of genomic alterations (including copy number variation, somatic Table 5 Gains of genomic material defined by two (or more) contiguous BAC clones Genomic profile of multiple myeloma MSCs M Garayoa et al mutations and/or loss of heterozygosity) in the stroma of several types of solid tumours [37] [38] [39] [40] [41] [42] [43] [44] Subsequently, genetically altered stromal cells would undergo clonal selection for stromal cells with the ability to modify tumour-stromal interactions and promote tumour growth. 26, 37 Even more, in a mouse model of prostate carcinoma, selection of genetic changes in the stroma have been found to occur from paracrine pressures imposed by oncogenic stress in the epithelium. 41 In this study, we conducted array-CGH to explore genomic changes in MSCs (as progenitor cells of stromal cells and osteoblasts in the BM) derived from MM patients, and to compare them with those in MSCs derived from normal donors. Besides, for each patient, the possibility of MSCs sharing the cytogenetic aberrations found in myelomatous PCs was also evaluated using FISH.
Our results from array-CGH show that the genomic profiles of ND-MSCs and of MM-MSCs after culture are clearly distinctive. In fact, ND-MSCs, as studied in P3, do not show genomic imbalances using array-CGH. Our finding is in agreement with that of other authors who have genetically characterized BM MSCs because of their potential use in cell therapy and tissue engineering approaches. These authors did not show evidence of chromosomal abnormalities in MSCs using cytogenetic analyses and array-CGH at time of collection, at passage 3 or even after prolonged in vitro culture. [45] [46] [47] [48] On the contrary, we have shown that in vitro expanded MSCs derived from MM patients present several gains and losses of genomic material, as defined by two contiguous-target BAC clones (41 Mb). In general, these alterations were not recurrent within the patients, as the highest frequency observed for a genomic deletion was 3 out of 21 MM-MSC samples (at 4p14-4p13), and another deletion occurring in two of MM-MSC samples (3q13.13); by contrast, no recurrence was observed for the rest of the deletions or at any of the genomic gains (see Tables 4 and 5 ). Although some of the implicated BAC clones did not encompass any known genes, other BACs harboured genes with potential biological interest in MSC physiology and/ or myeloma-stroma interactions (for example, bone morphogenetic protein 10 (BMP10), ephrin type-B receptor 1 (EPHB1), fibulin 5 EGF-like protein (FBLN5), receptor expressed in lymphoid tissues like 1 (RELL1), ADAM metallopeptidase with thrombospondin type 1 motif 17 (ADAMTS17)). Interestingly, for most affected patients, we found correlative deregulated expression for five genes encoded in the regions detected as genomic gains or losses using array-CGH (see Figure 6b ). These altered expressions may have an impact on the pathogenesis or the course of the disease. For example, a downregulated expression of BMP10 in MSCs may affect their osteoblastic differentiation capacity; the augmented levels of FBLN5, being a protein similar to epidermal growth factor, may promote the growth of myelomatous cells. The non-recurrent character of our results suggests that different stromal genomic alteration pathways 26, 37, 44 might be effective in creating a microenvironment permissive for the growth of MM cells.
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Supplementary Table 1 , with more frequent alterations in 6-3/ 21 patients, which supposes a 28-14% of MM patients in this study). One aspect to be considered is the putative biological significance of these multiple and small genomic alterations in the hot-spot regions. We can hypothesize that these zones might be more genetically unstable in MM-MSCs and may contain genes of importance in cancer progression; if that is the case, random amplification of discrete regions within these zones in MM-MSCs may affect expression of genes of importance to myeloma progression. In this sense, one of the detected hot-spot regions in our study is located at the terminal end of 17q (17q23.2-17q25.3), and contains 15 single-BAC gains of genomic material, with almost no recurrence within the patients, along a region encompassing E27 Mb. Recurrent partial gain of 17q material at a similar amplicon has also been reported in human embryonic stem cells in culture, 49 and in neuroblastoma, 50 breast 51, 52 and other types of cancers. These evidences are indicative that this region may house a number of genes that are important to malignant cells. 53 This could also be the case for MM-MSCs, and an increased genomic dosage of some of the affected 17q genes in the MSCs of certain patients may confer a stromal microenvironment advantageous to the growth of myeloma cells. Alternatively, the presence of these hot-spot regions with o1 Mb genomic alterations, although irrelevant per se, may predispose or may be a prerequisite for the occurrence of other genomic alterations of biological importance for neoplastic progression.
Validation of our array-CGH data was carried out for selected gains and losses of genomic material (including both X2 p18  d12  p1  p11  d3  d2  d4  d10  d1  d11  d7  p14  d5  d6  d8  d9  p21  p6  p17  p2  p7  p5  p9  p15  p13  p8  p3  p4  p10  p19  p12 p16 p20 Genomic profile of multiple myeloma MSCs M Garayoa et al flanking targets or single-target imbalances) using interphase FISH, using labelled BACs as probes. Four cases of amplifications and four deletions were tested on the correspondent MMMSCs cultured on slides ( Figure 5 ; Table 2 ). Although FISH analysis confirmed these genomic alterations, genomic mosaicism was observed in the MSC populations, with a variable number of cells harbouring the tested genetic alteration (45-80% of the cells were counted positive for the alteration; see Table 2 ). Likewise, we also attempted to confirm some of the more recurrent genomic alterations defined by single-target BACs (o1 Mb) using real-time PCR (gene copy number variation assay). In contrast to FISH validation, we were only able to validate one out of five single-target BAC alterations observed using array-CGH. This discrepancy could be explained by the relative low proportion of MSCs bearing the copy number variation. The theoretical difference between normal diploid copy and one allele deletion or duplication using real-time PCR should be 1 C t as long as 100% of the cells harboured such alteration. As the genomic alterations in this study were present only in a fraction of MSCs, the observed differences between normal and altered samples might be overlapped by the highest allowed deviation in real-time PCR replicates. Regardless of the impact that the genomic alterations found in MM-MSCs may have in the pathophysiology or in the course of the disease, considering the non-recurrent character of the genomic alterations together with the nature of the putative genes encoded in those genomic imbalances, it is our interpretation that these genomic alterations do not seem to be responsible, at least directly, for the functional and gene expression differences reported upon comparing MSCs derived from MM patients and those from normal donors. [12] [13] [14] Other genomic alterations, such as point mutations, loss of heterozygosity/allelic imbalance or epigenetic changes, or even a distinctive miRNA (microRNA) profile might be responsible for the commented differences. Alternatively, these gene expression differences in MSCs may rely on MM-stromal cell interactions, and subsequently remain present in a permanent fashion in in vitro MSC cultures in the absence of myeloma cells. 14 In view of our array-CGH results on in vitro expanded MSCs, it could be argued that the unbalanced genomic alterations observed in MM-MSCs at passage 3 could be a consequence of changes associated with the cell expansion process and adaptation to tissue culture conditions. To check whether uncultured MM-MSCs (passage 0) already harbour genomic abnormalities, freshly isolated BM stromal cells were sorted by expression of the specific phenotype CD45 54 genomic DNA was then isolated from these cells, subjected to amplification and analysed using array-CGH in a similar manner to array-CGH from cultured MSCs. This approach has already been validated by our group to obtain uncultured MSCs from BM aspirates of patients suffering from myelodysplastic syndrome 28 and yielded MSCs of 499% purity. As shown in Table 6 , genomic imbalances (41 Mb) were present in one out of five sorted MM-MSCs. We cannot rule out that the expansion process and adaptation to culture conditions may increase the genomic changes observed in the sorted population. Alternatively, although some MM-MSCs may already contain genomic alterations in the BM microenvironment, these alterations may not be present in a sufficient number of MSCs, as to be detected using array-CGH analysis on sorteduncultured MSCs, because of sensitivity limitations of this technique. It can be speculated that in vitro culture conditions may allow a positive clonal selection of those MM-MSCs that carry genomic alterations conferring an advantageous phenotype within the MSC population. The fact that our FISH confirmatory studies showed that the genetic changes were restricted to a fraction of MM-MSCs suggests that clonal selection processes are effectively occurring under culture. It is likely that a combination of both processes (adaptation of MSCs to culture conditions plus clonal selection) might be responsible for the higher ratio of patients with genomic aberrations in MM-MSCs at passage 3 as compared with sorted MSCs. Nevertheless, the absence of detectable genomic imbalances (41 Mb) and 'hot-spot regions' using array-CGH in ND-MSCs as compared with those in MM-MSCs after expansion, clearly establishes genomic differences for both types of MSCs.
Finally, we have tested the possibility that cytogenetic aberrations present in myeloma cells could also be present in the matching MM-MSCs. None of the MM-MSCs display the IGH translocations, nor RB or P53 deletions of myeloma cells. Our findings are in agreement with earlier studies in which MSCs from myeloma patients also failed to exhibit the chromosomal abnormalities detected in myeloma PCs. 12 Moreover, taking together that MM-MSCs do not contain myeloma-specific abnormalities and the fact that array-CGH profiles of myeloma cells 55 and those of MM-MSCs (present data) are clearly different, it should be concluded that genetic alterations of myeloma cells and BM stromal cells occur as independent events. Accordingly, a different origin for the MM-MSCs and for the neoplastic malignant clone should be postulated.
In conclusion, we have observed that cultured MSCs derived from MM patients present a distinctive array-CGH profile from that observed in their normal counterparts; these profiles are characterized by the presence of several non-recurrent gains and losses (41 Mb) of genetic material together with a specific pattern of 'hot-spot' regions with discrete (o1 Mb) genomic alterations. To which extent these structural aberrations in MMMSCs may have an impact on stromal cell function and, thus, on the progression/relapse of the disease still remains to be determined. In fact, functional and gene expression differences between MM-and ND-MSCs (in the absence of myeloma cell interactions) do not seem to be directly sustained by the genetic imbalances found in our study. In addition, we found that none of the MM-MSCs showed the cytogenetic abnormalities present in the myelomatous cells from the same patient. C o n t r o l P a t P a t # 1 0 P a t # 1 3 P a t # 1 5 C o n t r o l P a t P a t # 8 C o n t r o l P a t P a t # 1 7 C o n t r o l P a t P a t # 8 C o n t r o l P a t P a t # 1 7 P a t # 1 5 Gene expression assay for KCTD8 and BMP10 genes (located in lost DNA regions) and FBLN5, ZNF21, and ITPK1 genes (located at the regions of genomic gain). The expression levels for each target gene were quantified by real-time PCR and presented as the fold increase/decrease in affected patients relative to control patients. Results from control patients were normalized by setting the corresponding value as 1.
Table 6
Genomic imbalances (gains) found on sorted-uncultured MSCs defined by two (or more) contiguous BAC clones 
